Arca
Skip to content

Alzheimer's disease

Drug research and approvals for alzheimer's disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 622 studies of alzheimer's disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 151 drug trials for it since 2013, and the EU has 10 authorised medicines for it.

  • Recruiting worldwide: 622
  • Trials authorized in Canada: 151
  • FDA orphan approvals: 0
  • EU medicines: 10

Recruiting Now

Newest start dates first, of 622 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 151; search them all in Canada trials
Nov 3, 2026A rollover study to evaluate the safety, tolerability, and efficacy of long-term trontinemab administration in participants with alzheimer's diseaseTRONTINEMAB (RO7126209) / LANTHEUS ([18F]MK-6240)RochePending
Sep 25, 2026A proof-of-mechanism, open-label, parallel group study with an open-label extension phase to assess the safety, tolerability, pharmacokinetics, and…E2511 / [11C] MK 6884 / [18F] FEOBVEisaiPending
Aug 27, 2026A phase 2b, randomized, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of obicetrapib in participants with…OBICETRAPIB (TA-8995)NEWAMSTERDAM PHARMA B.V.Pending
Jul 21, 2026An open-label, dose escalation study to evaluate the safety, tolerability, and pharmacodynamics of vy1706 in participants with early alzheimer’s diseaseVY1706 / [18F]MK-6240 (ISOLOGIC)Voyager Therapeutics, Inc.Pending
Jun 25, 2026A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week sar448851 treatment followed by open-label…SAR448851 / [18F] MK-6240SANOFI-AVENTIS CANADA INCOngoing
Jun 25, 2026A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety study of trontinemab in cognitively unimpaired…TRONTINEMAB (RO7126209) / [18F]MK-6240 (LANTHEUS) / VIZAMYLRocheOngoing
Apr 23, 2026A phase 1/2a placebo-controlled dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of aro-mapt-sc in healthy…ADS-028 / [18F]MK-6240ARROWHEAD PHARMACEUTICALS, INC.Ongoing
Apr 16, 2026Evaluating treatment response in alzheimer's disease using [ 18fj flutemelamol petVIZAMYLUNIVERSITY OF SASKATCHEWANPending
Apr 7, 2026A phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of karxt + karx-ec for the treatment of…XANOMELINE-TROSPIUM (BMS-986510) / XANOMELINE (BMS-986519)Bristol-Myers SquibbPending
Dec 31, 2025Phase 2/3, double-blind, placebo-controlled study to evaluate the safety and efficacy of exv-802 and exv- 801 in the treatment of agitation in participants…DERAMCICLANE (EXV-801) / EXV-802 (DEXTROMETHORPHAN-DERAMCICLANE)EXCIVA GMBHOngoing

Medicines Authorised in the EU

Newest first
Sep 24, 2025KisunladonanemabEli Lilly Nederland B.V.EMA ↗
Apr 15, 2025LeqembilecanemabEisai GmbHEMA ↗
Dec 3, 2013Memantine Accordmemantine · genericAccord Healthcare S.L.U.EMA ↗
Jun 12, 2013Memantine ratiopharmmemantine · genericRatiopharm GmbHEMA ↗
Apr 28, 2013Marixino (previously Maruxa)memantine · genericKRKA tovarna zdravil d.d. Novo mestoEMA ↗
Apr 22, 2013Nemdatinememantine · genericActavis Group PTC ehfEMA ↗
Apr 21, 2013Memantine Mylanmemantine · genericMylan Pharmaceuticals LimitedEMA ↗
Nov 22, 2012Memantine Merzmemantine hydrochlorideMerz Pharmaceuticals GmbHEMA ↗
May 17, 2002AxuramemantineMerz Pharmaceuticals GmbHEMA ↗
May 15, 2002EbixamemantineH. Lundbeck A/SEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.